Tarsus Pharmaceuticals, Inc.
TARS • NASDAQ
Tarsus Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Bobak R. Azamian, with a market cap of $3.1B.
CEOBobak R. Azamian
Next Earnings
Upcoming earnings announcement for Tarsus Pharmaceuticals, Inc.
Date
Thursday, April 30, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.33
Revenue Estimate
$150.3M
Earnings History
Past 12 earnings reports for Tarsus Pharmaceuticals, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 23, 2026 | Q4 2025 | -$0.20Est: -$0.07 | -185.7% | $151.7MEst: $144.7M | +4.8% |  10-K |
| Nov 4, 2025 | Q3 2025 | -$0.30Est: -$0.34 | +11.8% | $118.7MEst: $115.3M | +2.9% | 10-Q |
| Aug 6, 2025 | Q2 2025 | -$0.48Est: -$0.35 | -37.1% | $102.7MEst: $94.8M | +8.2% | 10-Q |
| May 1, 2025 | Q1 2025 | -$0.64Est: -$0.63 | -1.6% | $78.3MEst: $71.6M | +9.4% | 10-Q |
| Feb 25, 2025 | Q4 2024 | -$0.60Est: -$0.82 | +26.8% | $66.4MEst: $58.8M | +12.9% | 10-K |
| Nov 13, 2024 | Q3 2024 | -$0.61Est: -$0.94 | +35.1% | $48.1MEst: $43.4M | +10.8% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.88Est: -$0.93 | +5.4% | $40.8MEst: $31.7M | +28.7% | 10-Q |
| May 8, 2024 | Q1 2024 | -$1.01Est: -$1.20 | +15.8% | $27.6MEst: $17.8M | +54.9% | 10-Q |
| Feb 27, 2024 | Q4 2023 | -$1.31Est: -$1.36 | +3.7% | $13.1MEst: $5.7M | +131.0% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$1.28Est: -$1.36 | +5.9% | $1.9MEst: $400.0K | +367.8% | — |
| Aug 10, 2023 | Q2 2023 | -$1.17Est: -$1.08 | -8.3% | - | — | 10-Q |
| May 9, 2023 | Q1 2023 | -$0.88Est: -$0.94 | +6.4% | $2.5MEst: $3.1M | -19.9% | — |